HealthWarehouse.com, Inc. revealed that its net sales for the first quarter ending March 31, 2026, were $6.3 million, marking a 58% drop compared to the same period in 2025. This decline was attributed to the conclusion of a nationwide shortage by the U.S. Food and Drug Administration, which had permitted pharmacies to produce and sell compounded GLP-1 prescription drugs when brand-name options were scarce. The company reported a net loss of $361,000 and an Adjusted EBITDA figure that was negative.
